Free tool
FAERS Monitor: Baqsimi
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 210134 or its brand name (Baqsimi, Glucagon). Reports on generic versions are filed under their own applications.
Reports
4,232
Serious
3,276
77% of reports
Hospitalization
2,036
Death reported
676
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective389
- dyspnoea375
- acute kidney injury324
- hypotension300
- hypoglycaemia271
- condition aggravated258
- toxicity to various agents238
- nausea237
- anxiety226
- haemoptysis224
- vomiting222
- death213
- pain in extremity212
- off label use206
- blood glucose increased201
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 19 |
| 2005 | 24 |
| 2006 | 20 |
| 2007 | 26 |
| 2008 | 23 |
| 2009 | 49 |
| 2010 | 34 |
| 2011 | 53 |
| 2012 | 53 |
| 2013 | 54 |
| 2014 | 83 |
| 2015 | 230 |
| 2016 | 202 |
| 2017 | 210 |
| 2018 | 207 |
| 2019 | 323 |
| 2020 | 448 |
| 2021 | 436 |
| 2022 | 316 |
| 2023 | 398 |
| 2024 | 369 |
| 2025 | 392 |
| 2026 | 263 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,927 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| haemoptysisSignal | 224 | 40.2 | 35.4 | 8,474 |
| hypoglycaemiaSignal | 271 | 27.9 | 24.9 | 6,984 |
| acute kidney injurySignal | 324 | 10.5 | 9.5 | 2,803 |
| hypotensionSignal | 300 | 7.4 | 6.7 | 1,680 |
| toxicity to various agentsSignal | 238 | 7.0 | 6.2 | 1,231 |
| blood glucose increasedSignal | 201 | 5.3 | 4.6 | 704 |
| condition aggravatedSignal | 258 | 4.2 | 3.7 | 639 |
| anxietySignal | 226 | 3.9 | 3.5 | 501 |
| pain in extremitySignal | 212 | 3.6 | 3.1 | 396 |
| dyspnoeaSignal | 375 | 3.3 | 3.0 | 613 |
| vomitingSignal | 222 | 2.3 | 2.1 | 174 |
| nausea | 237 | 1.5 | 1.3 | 39 |
| drug ineffective | 389 | 1.5 | 1.3 | 61 |
| death | 213 | 1.2 | 1.1 | 9 |
| off label use | 206 | 1.2 | 1.0 | 5 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.